Hvsen Biotechnology Past Earnings Performance
Past criteria checks 2/6
Hvsen Biotechnology's earnings have been declining at an average annual rate of -58.5%, while the Pharmaceuticals industry saw earnings growing at 6.8% annually. Revenues have been growing at an average rate of 11.2% per year. Hvsen Biotechnology's return on equity is 2.6%, and it has net margins of 2.9%.
Key information
-58.49%
Earnings growth rate
-67.03%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.90% |
| Revenue growth rate | 11.20% |
| Return on equity | 2.61% |
| Net Margin | 2.93% |
| Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
Recent updates
Improved Revenues Required Before Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stock's 30% Jump Looks Justified
Mar 25
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Not Doing Enough For Some Investors As Its Shares Slump 25%
Jan 03Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Nov 14Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Sep 30Hvsen Biotechnology Co., Ltd. (SZSE:300871) Shares Could Be 21% Below Their Intrinsic Value Estimate
Aug 21Take Care Before Jumping Onto Hvsen Biotechnology Co., Ltd. (SZSE:300871) Even Though It's 27% Cheaper
Jun 05Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stocks Shoot Up 37% But Its P/E Still Looks Reasonable
Mar 29Revenue & Expenses Breakdown
How Hvsen Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 25 | 1,393 | 41 | 125 | 56 |
| 31 Dec 24 | 1,200 | -20 | 118 | 56 |
| 30 Sep 24 | 1,121 | -46 | 156 | 52 |
| 30 Jun 24 | 1,007 | -51 | 155 | 52 |
| 31 Mar 24 | 996 | -14 | 155 | 50 |
| 31 Dec 23 | 1,020 | 17 | 155 | 45 |
| 30 Sep 23 | 1,043 | 41 | 129 | 45 |
| 30 Jun 23 | 1,075 | 62 | 122 | 42 |
| 31 Mar 23 | 1,048 | 66 | 115 | 40 |
| 01 Jan 23 | 1,023 | 53 | 113 | 40 |
| 30 Sep 22 | 922 | 40 | 84 | 45 |
| 30 Jun 22 | 857 | 38 | 80 | 49 |
| 31 Mar 22 | 888 | 71 | 83 | 51 |
| 01 Jan 22 | 996 | 133 | 81 | 47 |
| 30 Sep 21 | 1,027 | 173 | 104 | 41 |
| 30 Jun 21 | 1,026 | 199 | 105 | 34 |
| 31 Mar 21 | 956 | 188 | 99 | 31 |
| 31 Dec 20 | 777 | 150 | 91 | 28 |
| 30 Sep 20 | 655 | 130 | 79 | 22 |
| 31 Dec 19 | 427 | 69 | 64 | 21 |
| 31 Dec 18 | 422 | 71 | 79 | 20 |
| 31 Dec 17 | 400 | 88 | 78 | 18 |
| 31 Dec 16 | 258 | 49 | 63 | 13 |
Quality Earnings: 300871 has high quality earnings.
Growing Profit Margin: 300871 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300871's earnings have declined by 58.5% per year over the past 5 years.
Accelerating Growth: 300871 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 300871 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.9%).
Return on Equity
High ROE: 300871's Return on Equity (2.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 04:57 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hvsen Biotechnology Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiarui Lu | Guosen Securities Co., Ltd. |